← 返回

巨噬细胞:头颈部鳞状细胞癌诊断和治疗中的可塑性参与者

英文原题:Macrophages: plastic participants in the diagnosis and treatment of head and neck squamous cell carcinoma.

查看英文原题

Macrophages: plastic participants in the diagnosis and treatment of head and neck squamous cell carcinoma.

PubMed 2024/04/08(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

头颈部鳞状细胞癌(HNSCC)是全球最常见的头颈部癌症类型之一。遗憾的是,大量患者在确诊时已处于晚期,限制了现有治疗手段的有效性。肿瘤微环境(TME)在 HNSCC 的发生发展中起着关键作用,其中巨噬细胞占据核心地位。巨噬细胞在 TME 中表现出多样化的功能,既抑制也促进癌症进展。M1 型巨噬细胞以吞噬和免疫活性为特征,而 M2 型巨噬细胞则倾向于促进炎症和免疫抑制。在这些不同极化状态之间保持平衡对维持整体健康至关重要,然而在肿瘤环境中,M2 型巨噬细胞通常占优势。近年来的研究致力于调控巨噬细胞的极化状态,为癌症治疗开辟了新途径。多种药物和免疫疗法已被开发,包括基于巨噬细胞的创新疗法,如工程化巨噬细胞和 CAR-M 细胞疗法。本文概述了巨噬细胞在 HNSCC 中所发挥的作用,探讨了潜在的治疗靶点和策略,并对 HNSCC 治疗的未来提出了新的展望。

展开英文摘要原文

Head and neck squamous cell carcinoma (HNSCC) rank among the most prevalent types of head and neck cancer globally. Unfortunately, a significant number of patients receive their diagnoses at advanced stages, limiting the effectiveness of available treatments. The tumor microenvironment (TME) is a pivotal player in HNSCC development, with macrophages holding a central role. Macrophages demonstrate diverse functions within the TME, both inhibiting and facilitating cancer progression. M1 macrophages are characterized by their phagocytic and immune activities, while M2 macrophages tend to promote inflammation and immunosuppression.

Striking a balance between these different polarization states is essential for maintaining overall health, yet in the context of tumors, M2 macrophages typically prevail. Recent efforts have been directed at controlling the polarization states of macrophages, paving the way for novel approaches to cancer treatment.

Various drugs and immunotherapies, including innovative treatments based on macrophages like engineering macrophages and CAR-M cell therapy, have been developed. This article provides an overview of the roles played by macrophages in HNSCC, explores potential therapeutic targets and strategies, and presents fresh perspectives on the future of HNSCC treatment.

论文信息

作者
Lin C、Chu Y、Zheng Y、Gu S、Hu Y、He J、Shen Z
单位
The Affiliated Lihuili Hospital, Ningbo University, Ningbo, China.China
文献类型
综述 · 非美国政府资助研究
期刊
Frontiers in immunology2024
原文标识
PubMed 38650924 · DOI 10.3389/fimmu.2024.1337129